Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 10/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | BTK | Q06187 | 3/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
| ▸ | CCR8 | P51685 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16591620 | 0.83 | BTK (0.40) | EPHX2EPHX1BTKSMYD3 | |
| SCHEMBL15337918 | 0.79 | EPHX1 (0.53) | EPHX2EPHX1CCR8 | |
| SCHEMBL12017963 | 0.79 | EPHX2 (0.51) | EPHX2EPHX1MEN1KMT2ACCR8 | |
| SCHEMBL23691784 | 0.78 | BTK (0.37) | BTKSMYD3CCR8 | |
| SCHEMBL11324301 | 0.76 | EPHX2 (0.49) | EPHX2EPHX1MEN1KMT2ACCR8 | |
| SCHEMBL24435818 | 0.75 | EPHX2 (0.50) | EPHX2EPHX1MEN1KMT2ACCR8 | |
| SCHEMBL14175034 | 0.72 | EPHX2 (0.56) | EPHX2EPHX1 | |
| SCHEMBL315541 | 0.72 | EPHX2 (0.56) | EPHX2EPHX1 | |
| SCHEMBL10693905 | 0.72 | CA12 (0.52) | SMYD3 | |
| SCHEMBL25932444 | 0.71 | EPHX2 (0.47) | EPHX2EPHX1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242548-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-08-03 | — | — | US | disclosed |
| US-20160368930-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368930-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | EPHX2 2775/4885EPHX1 2274/4885MEN1 2804/4885 |
| US-20230242548-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | EPHX2 2775/4885EPHX1 2274/4885MEN1 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.